30 Results for "

RNA interference

" in MedChemExpress (MCE) Product Catalog:
Products (30)

30 Results for "RNA interference" in MCE Product Catalog:

Cat. No.: HY-147425D
Synonyms: FAM labled SLN360 sodium
FAM labled Zerlasiran sodium is a FAM labled Zerlasiran sodium (HY-147425A). Zerlasiran sodium is a siRNA targeting apolipoprotein A (ApoA). Zerlasiran sodium targets hepatic ApoA synthesis via RNA interference to degrade encoding mRNA. Zerlasiran sodium can be used for the research of atherosclerotic cardiovascular disease and elevated ApoA levels .
loading...
    loading...
Cat. No.: HY-147425E
Synonyms: Cy3 labled SLN360 sodium
Cy3 labled Zerlasiran sodium is a Cy3 labled Zerlasiran sodium (HY-147425A). Zerlasiran sodium is a siRNA targeting apolipoprotein A (ApoA). Zerlasiran sodium targets hepatic ApoA synthesis via RNA interference to degrade encoding mRNA. Zerlasiran sodium can be used for the research of atherosclerotic cardiovascular disease and elevated ApoA levels .
loading...
    loading...
Cat. No.: HY-147425C
Synonyms: SLN360 sodium scrambled negative control
Zerlasiran (SLN360) sodium scrambled negative control is the sequence scrambled negative control of Zerlasiran sodium (HY-147425A). Zerlasiran sodium is a siRNA targeting apolipoprotein A (ApoA). Zerlasiran sodium targets hepatic ApoA synthesis via RNA interference to degrade encoding mRNA. Zerlasiran sodium can be used for the research of atherosclerotic cardiovascular disease and elevated ApoA levels .
loading...
    loading...
Cat. No.: HY-187051
CAS No.: 1953147-04-0
Target:  

Phosphoramidites

Research Areas:  

Metabolic Disease

AdemG Phosphoramidite is a ligand-conjugated phosphoramidite synthon. AdemG Phosphoramidite can be used for the synthesis of GalNAc-conjugated siRNA and DsiRNA for liver-targeted gene silencing .
loading...
    loading...
Cat. No.: HY-K0002

MCE Bacterial Protein Extraction Reagent integrates both lysozyme and nuclease activities and is specifically formulated for E. coli lysis. It efficiently disrupts the peptidoglycan layer under mild conditions to rapidly release intracellular proteins. Simultaneously, the incorporated nucleases degrade genomic DNA/RNA, significantly reducing lysate viscosity and minimizing nucleic-acid interference, thereby preserving the native conformation and functional integrity of target proteins to the greatest extent.

loading...
    loading...
Cat. No.: HY-177646C
Research Areas:  

Neurological Disease

FAM labled Mivelsiran (ALN-APP) sodiumis a FAM labled Mivelsiran sodium. Mivelsiran sodium is an siRNA targeting the β-amyloid precursor protein (APP). Mivelsiran sodium induces sequence-specific degradation of APP mRNA via RNA interference, thereby reducing the levels of APP protein and downstream amyloid cleavage products. Mivelsiran sodium reduces β-amyloid protein levels in the brain, alleviates neuroinflammation, and attenuates microglial proliferation. Mivelsiran sodium can be used for research on early-onset Alzheimer's disease .
loading...
    loading...
Cat. No.: HY-177646D
Research Areas:  

Neurological Disease

Cy3 labled Mivelsiran (ALN-APP) sodium is a Cy3 labled Mivelsiran sodium. Mivelsiran sodium is an siRNA targeting the β-amyloid precursor protein (APP). Mivelsiran sodium induces sequence-specific degradation of APP mRNA via RNA interference, thereby reducing the levels of APP protein and downstream amyloid cleavage products. Mivelsiran sodium reduces β-amyloid protein levels in the brain, alleviates neuroinflammation, and attenuates microglial proliferation. Mivelsiran sodium can be used for research on early-onset Alzheimer's disease .
loading...
    loading...
Cat. No.: HY-107620R
CAS No.: 212631-61-3
Target:  

Reference Standards MEK

Research Areas:  

Neurological Disease

PD 198306 (Standard) is the analytical standard of PD 198306 (HY-107620). This product is intended for research and analytical applications. PD 198306 is a selective MAPK/ERK-Kinase (MEK) inhibitor. PD 198306 results in an observable reduction in the Streptozocin induced increase in the level of active ERK1 and 2. Antihyperalgesic effects .
loading...
    loading...
Cat. No.: HY-176522
Research Areas:  

Cancer

Oligomer-lipid 7C1 is an ionazable lipid. Oligomer-lipid 7C1 can be generated through the reaction of low-molecular-weight polyamine with lipid. Oligomer-lipid 7C1 efficiently binds siRNA to form nanoparticle. Oligomer-lipid 7C1 can induce RNA interference in endothelial cells of multiple organs in nonhuman primates. Oligomer-lipid 7C1 is able to deliver siRNA to endothelial cells and facilitates endothelial function modification in mouse models of vascular permeability, emphysema, primary tumor growth and metastasis .
loading...
    loading...
Cat. No.: HY-L158
6,342 compounds

According to reports, most known kinase inhibitors exert their effects through competitive binding in highly conserved ATP pockets. Although genetic techniques such as RNA interference can inactivate specific genes, most kinases are multi domain proteins, each of which has an independent function. Highly selective inhibitors have higher efficiency than non-selective inhibitors, and the selectivity to the target is at least 100 times higher. Therefore, ensuring the validation of targets with the most selective inhibitors is crucial for a more thorough understanding of the pharmacology of the kinase field. The Highly Selective Inhibitors Library contains 6,342 compounds, covering multiple targets and subtypes, such as GPCR protein family, Ion channel, multiple kinases, etc. The Highly Selective Inhibitors Library is an effective tool for screening different phenotypes